Open Access

Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild‑type epidermal growth factor receptor

  • Authors:
    • Takumi Yamaura
    • Junji Ezaki
    • Naoyuki Okabe
    • Hironori Takagi
    • Yuki Ozaki
    • Takuya Inoue
    • Yuzuru Watanabe
    • Mitsuro Fukuhara
    • Satoshi Muto
    • Yuki Matsumura
    • Takeo Hasegawa
    • Mika Hoshino
    • Jun Osugi
    • Yutaka Shio
    • Satoshi Waguri
    • Hirosumi Tamura
    • Jun‑Ichi Imai
    • Emi Ito
    • Yuka Yanagisawa
    • Reiko Honma
    • Shinya Watanabe
    • Hiroyuki Suzuki
  • View Affiliations

  • Published online on: December 5, 2017     https://doi.org/10.3892/ol.2017.7517
  • Pages:1549-1558
  • Copyright: © Yamaura et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Lung adenocarcinoma (ADC) patients with tumors that harbor no targetable driver gene mutation, such as epidermal growth factor receptor (EGFR) gene mutations, have unfavorable prognosis, and thus, novel therapeutic targets are required. Family with sequence similarity 83, member B (FAM83B) is a biomarker for squamous cell lung cancer. FAM83B has also recently been shown to serve an important role in the EGFR signaling pathway. In the present study, the molecular and clinical impact of FAM83B in lung ADC was investigated. Matched tumor and adjacent normal tissue samples were obtained from 216 patients who underwent complete lung resection for primary lung ADC and were examined for FAM83B expression using cDNA microarray analysis. The associations between FAM83B expression and clinicopathological parameters, including patient survival, were examined. FAM83B was highly expressed in tumors from males, smokers and in tumors with wild‑type EGFR. Multivariate analyses further confirmed that wild‑type EGFR tumors were significantly positively associated with FAM83B expression. In survival analysis, FAM83B expression was associated with poor outcomes in disease‑free survival and overall survival, particularly when stratified against tumors with wild‑type EGFR. Furthermore, FAM83B knockdown was performed to investigate its phenotypic effect on lung ADC cell lines. Gene silencing by FAM83B RNA interference induced growth suppression in the HLC‑1 and H1975 lung ADC cell lines. FAM83B may be involved in lung ADC tumor proliferation and can be a predictor of poor survival. FAM83B is also a potential novel therapeutic target for ADC with wild‑type EGFR.

Related Articles

Journal Cover

February 2018
Volume 15 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yamaura, T., Ezaki, J., Okabe, N., Takagi, H., Ozaki, Y., Inoue, T. ... Suzuki, H. (2018). Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild‑type epidermal growth factor receptor. Oncology Letters, 15, 1549-1558. https://doi.org/10.3892/ol.2017.7517
MLA
Yamaura, T., Ezaki, J., Okabe, N., Takagi, H., Ozaki, Y., Inoue, T., Watanabe, Y., Fukuhara, M., Muto, S., Matsumura, Y., Hasegawa, T., Hoshino, M., Osugi, J., Shio, Y., Waguri, S., Tamura, H., Imai, J., Ito, E., Yanagisawa, Y., Honma, R., Watanabe, S., Suzuki, H."Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild‑type epidermal growth factor receptor". Oncology Letters 15.2 (2018): 1549-1558.
Chicago
Yamaura, T., Ezaki, J., Okabe, N., Takagi, H., Ozaki, Y., Inoue, T., Watanabe, Y., Fukuhara, M., Muto, S., Matsumura, Y., Hasegawa, T., Hoshino, M., Osugi, J., Shio, Y., Waguri, S., Tamura, H., Imai, J., Ito, E., Yanagisawa, Y., Honma, R., Watanabe, S., Suzuki, H."Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild‑type epidermal growth factor receptor". Oncology Letters 15, no. 2 (2018): 1549-1558. https://doi.org/10.3892/ol.2017.7517